Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: Mays, speaking to a TV critics’ meeting Friday, pointed to several bottles she had filled with her tap water and challenged the room to taste or even smell it. There were no immediate takers. The activist, who said the battle over water safety continues, is among the residents portrayed in Lifetime’s movie titled “Flint,” debuting Oct. 28. Mays is played by Marin Ireland, who co-stars with Betsy Brandt, Jill Scott and Queen Latifah. Executive producer Neil Meron said the film is intended to spotlight what happened in Flint, including how a united community and “the voice of the people” can force officials to act. Mays said there have been successes, including the outcome of a lawsuit to get half of the service lines replaced, although not the main lines or interior plumbing. “So one of the things we hope come out of this is to let people know it’s still not over. It’s not even close to over,” she said. The movie is intended to honor Flint victims by telling the story “that even in a poor, broken, poisoned town, we banded together, and we fought. We fought, and we win.” In 2014, a switch of Flint’s water source and failure to add corrosion-reducing phosphates allowed lead from old pipes to leach into the water. Elevated levels of lead, a neurotoxin, were detected in children, and 12 people died in a Legionnaires’ disease outbreak that experts suspect was linked to the improperly treated water. An ongoing investigation has led to charges against 13 current or former government officials, including two managers who Republican Gov. Rick Snyder appointed to run the city. Last January, state officials said Flint’s water system no longer has lead levels exceeding the federal limit. The announcement was promptly met by skepticism from some residents, Mays among them, maintaining the system still contains lead and continues to cause illness. Brandt, the former “Breaking Bad” star who’s a native of Bay City, Michigan, not far from Flint, said the person she portrays, LeeAnne Walters, was among those driven to act when authorities failed to heed complaints about their children becoming ill. “As a mom, it just shakes you, because there’s some things that we just should be able to count on,” Brandt said. Claim: Lifetime movie ‘Flint’ dramatizes city’s water crisis.
Example Output: Melissa Mays, a resident of Flint, Michigan, came armed to discuss the city’s tainted water crisis and a new Lifetime TV movie dramatizing it.

Example Input: Paragraph: Cancer patients increasingly are having their care guided by gene tumor boards, a new version of the hospital panels that traditionally decided whether surgery, radiation or chemotherapy would be best. These experts study the patient’s cancer genes and match treatments to mutations that seem to drive the disease. “We dissect the patient’s tumor with what I call the molecular microscope,” said Dr. Razelle Kurzrock, who started a board at the University of California, San Diego, where Cairnes is treated. It’s the kind of care many experts say we should aim for — precision medicine, the right drug for the right person at the right time, guided by genes. There are success stories, but also some failures and many questions: Will gene-guided care improve survival? Does it save money or cost more? What kind of gene testing is best, and who should get it? “I think every patient needs it,” especially if cancer is advanced, said Kurzrock, who consults for some gene-medicine companies. “Most people don’t agree with me — yet. In five years, it may be malpractice not to do genomics.” Few people get precision medicine today, said Dr. Eric Topol, head of the Scripps Translational Science Institute. “The only thing that’s gone mainstream are the words.” HOW IT WORKS NOW If you have a cancer that might be susceptible to a gene-targeting drug, you may be tested for mutations in that gene, such as HER2 for breast cancer. Some breast or prostate cancer patients also might get a multi-gene test to gauge how aggressive treatment should be. Then most patients get usual guideline-based treatments. If there’s no clear choice, or if the disease has spread or comes back, doctors may suggest tumor profiling — comprehensive tests to see what mutations dominate. That’s traditionally been done from a tissue sample, but newer tests that detect tumor DNA in blood — liquid biopsies — are making profiling more common. The tests cost about $6,000 and many insurers consider them experimental and won’t pay. Gene tumor boards analyze what the results suggest about treatment. They focus on oddball cases like a breast cancer mutation in a colon cancer patient, or cancers that have widely spread and are genetically complex. The only options may be experimental drugs or “off-label” treatments — medicines approved for different situations. But as tumor profiling grows, it’s revealing how genetically diverse many tumors are, and that oddball cases are not so rare, said Dr. John Marshall. He heads the virtual tumor board at Georgetown Lombardi Comprehensive Cancer Center that also serves cancer centers in Pennsylvania, North Carolina, Michigan and Tennessee. “There is a little bit of faith” that testing will show the right treatment, but it’s not a sure thing, said Dr. Lee Schwartzberg, who heads one participating center, the West Cancer Center in Memphis. Dr. Len Lichtenfeld, the American Cancer Society’s deputy chief medical officer, is optimistic yet wary. Drugs that target BRAF mutations work well for skin cancers called melanomas, but less well for lung or colon cancers. “Just because a mutation occurs it doesn’t mean that drug is going to work in that cancer,” he said. LUCKY CASES When it does, results can be dramatic. Cairnes’ cancer was between her stomach and esophagus, and had spread to her liver, lungs and lymph nodes. Tissue testing found 10 abnormal genes, but on the liquid biopsy only EGFR popped out as a good target. Two drugs aim at that gene but aren’t approved for her type of cancer. A tumor board advised trying both — Erbitux and Tarceva, the drug her husband also had taken. Within two weeks, she quit using pain medicines. After two months, her liver tumor had shrunk roughly by half. There are signs that cancer may remain, but it is under control. She feels well enough to travel and to take care of her granddaughter. “I’m very, very grateful to have a targeted therapy,” Cairnes said. “I cannot expect a better outcome than what we’re seeing right now,” said her doctor, Shumei Kato. WHAT STUDIES SHOW But is gene-guided treatment better than usual care? French doctors did the first big test, with disappointing results. About 200 patients with advanced cancer were given whatever their doctors thought best or off-label drugs based on tumor profiling. Survival was similar — about two months. Another French study, reported in June, was slightly more encouraging on survival but exposed another problem: No drugs exist for many gene flaws. Tests found treatable mutations in half of the 2,000 participants and only 143 got what a tumor board suggested. Some doctors worry that tumor boards’ recommending off-label treatments diverts patients from research that would benefit all cancer patients. For example, the American Society of Clinical Oncology’s TAPUR study tests off-label drugs and shares results with their makers and federal regulators. LETTING PATIENTS CHOOSE Ann Meffert, who lives on a dairy farm in Waunakee, Wisconsin, endured multiple standard treatments that didn’t defeat her bile duct cancer. “She was going to be referred to hospice; there was not much we could do,” said Dr. Nataliya Uboha, who took the case to a tumor board at the University of Wisconsin-Madison. The panel gave several options, including off-label treatment, and Meffert chose a study that matches patients to gene-targeting therapies and started on an experimental one last October. “Two weeks in, I started feeling better,” she said, and when she saw test results, “I couldn’t believe the difference.” Many lung spots disappeared and the liver tumor shrank 75 percent. She is not cured, though, and doctors are thinking about next steps. And that could involve a fresh look at her tumor genes. ___ Marilynn Marchione can be followed at @MMarchioneAP __ This Associated Press series was produced in partnership with the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. Claim: Ultra-personal therapy: Gene tumor boards guide cancer care.
Example Output: Doctors were just guessing a decade ago when they gave Alison Cairnes’ husband a new drug they hoped would shrink his lung tumors. Now she takes it, but the choice was no guesswork. Sophisticated gene tests suggested it would fight her gastric cancer, and they were right.

Example Input: Paragraph: The disease being called “pediatric multisystem inflammatory syndrome” was identified and treated at Seattle Children’s Hospital, KUOW reported. King County Public Health said the patient was a resident of Snohomish County and there have been no other confirmed cases in the area. It involves a “hyper response” of the child’s immune system to the virus, according to Dr. Michael Portman, who directs pediatric cardiovascular research at Children’s. It can lead to inflammation of the blood vessels, and affect the heart’s arteries, leading to coronary aneurysms. In similar diseases, that can lead to lifelong heart issues, Portman said. The syndrome is rare and most children infected with the virus develop only mild illness. The disease is being linked to COVID-19, Portman said, because almost all of the patients have had confirmed cases of the virus, positive antibody tests, or known exposure. Portman said it is very similar and at times appears almost identical to a disease called “Kawasaki disease,” which was identified in Japan in the 1960s. According to Portman, Kawasaki disease is fairly common at Seattle Children’s. Around 30% patients at Children’s with Kawasaki disease are of Asian descent, Portman said. But the disease “seems to affect Hispanic and black children more severely” due to a “more robust inflammatory response.” Most of the cases of the new syndrome have been in the New York area and a handful have been fatal. Portman’s advice to parents is “not to freak out,” but if a child has a persistent fever, which is a symptom, he recommends getting it checked. Claim: Seattle sees 1st case of childhood disease tied to virus.
Example Output:
Seattle has had its first confirmed case of a rare inflammatory disease in children closely tied to COVID-19.